3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
4
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
48
Neoplasms
13
Sarcoma
10
Neoplasm Metastasis
9
Triple Negative Breast Neoplasms
8
Carcinoma, Non-Small-Cell Lung
5
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Prostatic Neoplasms
2
Colorectal Neoplasms
2
Urinary Bladder Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Recurrence
1
Peripheral Nervous System Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Metastatic HER2-positive Breast Cancer
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Melanoma
1
Lymphoma
1
Lung Neoplasms
1
Inoperable Locally Advanced HER2-Negative Breast Cancer
1
HR+HER2- Breast Cancer
1
HER2-low Breast Cancer
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Interventions
Temozolomide
29
Bevacizumab
14
Radiotherapy
12
Trastuzumab
10
Lomustine
9
Capecitabine
8
paclitaxel-Angiopep-2 conjugate
6
Nivolumab
6
pembrolizumab
5
dabrafenib
5
abemaciclib
5
Radiation
5
icotinib
4
Surgical Procedures, Operative
4
Paclitaxel
4
Lapatinib
4
Irinotecan
4
Flucytosine
4
Dianhydrogalactitol
4
Corticotropin-Releasing Hormone
4
Chlorotoxin
4
Carboplatin
4
vocimagene amiretrorepvec
3
verubulin
3
tucatinib
3
osimertinib
3
motexafin gadolinium
3
XL647
3
Spermine Synthase
3
Radiosurgery
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Brain Neoplasms
×
eribulin
×
Clear all
NCT03613181
2023-04-24
ANGLeD
Angiochem Inc
Phase 3
Unknown
150 enrolled